Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Ohio State University Comprehensive Cancer Center
With
Immunex Corporation
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Must have pathologically or cytologically confirmed advanced solid malignancy for which there is no standard treatment exists.
Solid malignancy that has persisted or recurred following prior therapy or advanced solid malignancy for which docetaxel is considered an acceptable first line treatment option:
* Non-Small Cell Lung
* Breast
* Head and Neck
* Esophageal
* Stomach
* Ovarian carcinomas
Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2
Life expectancy of at least 12 weeks.
Must have adequate organ function
Peripheral Neuropathy must be less than Grade 2
Clareo Health | Phase I & Biological Study of Etanercept & Weekly Docetaxel in Patients With Advanced Solid Tumors
